Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal tolerability of 15-minute versus 60-minute Bondronat infusion in patients with bone metastases
2006-000608-18Phase 2Active
- Sponsor
- Roche Farma, S.A.
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ibandronic acid in bone metastases (2 arms), sponsored by Roche Farma, S.A. Primary endpoint: Renal tolerability. Started Apr 2006; status: active.
02
Drugs
ibandronic acid
03
Conditions
bone metastases
Beyond the preview
Go deeper on 2006-000608-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000608-18.